Development · 25 Sep 2026
CRISIL, full dossier3 publishers have reported this development. Each act of reporting is below, cited.
India's pharmaceutical sector is poised for a stronger dose of revenue growth at 11-13 percent this fiscal year compared to 8 percent a year earlier, driven by accelerating exports and firmer domestic demand, according to a report by Crisil Ratings.
Accelerating exports and firmer domestic demand could help grow the Indian pharmaceutical sector 11-13%, higher than the 8% revenue growth it registered last fiscal, according to rating agency Crisil Ratings.
Indian pharma revenue growth is expected to accelerate to 11-13 per cent this fiscal from 8 per cent last year, driven by a 14-16 per cent rise in exports.
1 Oct 2026 · 1 publisher
30 Sep 2026 · 1 publisher
30 Sep 2026 · 1 publisher
20 Sep 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.